S&P 500   3,936.97 (-1.65%)
DOW   32,030.11 (-1.63%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PFE   40.01 (-1.60%)
PYPL   74.34 (-3.10%)
NFLX   293.90 (-3.89%)
S&P 500   3,936.97 (-1.65%)
DOW   32,030.11 (-1.63%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PFE   40.01 (-1.60%)
PYPL   74.34 (-3.10%)
NFLX   293.90 (-3.89%)
S&P 500   3,936.97 (-1.65%)
DOW   32,030.11 (-1.63%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PFE   40.01 (-1.60%)
PYPL   74.34 (-3.10%)
NFLX   293.90 (-3.89%)
S&P 500   3,936.97 (-1.65%)
DOW   32,030.11 (-1.63%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PFE   40.01 (-1.60%)
PYPL   74.34 (-3.10%)
NFLX   293.90 (-3.89%)
NASDAQ:RDHL

RedHill Biopharma - RDHL Stock Forecast, Price & News

$0.14
0.00 (-0.29%)
(As of 03/22/2023 05:12 PM ET)
Add
Compare
Today's Range
$0.13
▼
$0.14
50-Day Range
$0.14
▼
$0.26
52-Week Range
$0.13
▼
$3.27
Volume
1.54 million shs
Average Volume
6.99 million shs
Market Capitalization
$13.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

RedHill Biopharma MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
6.65% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.66mentions of RedHill Biopharma in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.65) to ($0.60) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.44 out of 5 stars

Medical Sector

917th out of 983 stocks

Pharmaceutical Preparations Industry

446th out of 478 stocks

See Top Rated MarketRank™ Stocks Here

RDHL stock logo

About RedHill Biopharma (NASDAQ:RDHL) Stock

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Receive RDHL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RedHill Biopharma and its competitors with MarketBeat's FREE daily newsletter.

RDHL Stock News Headlines

March 21, 2023 | finance.yahoo.com
RedHill Initiates First Community-Setting Warranty Program to Refund Talicia Non-Responders
March 19, 2023 | americanbankingnews.com
RedHill Biopharma Stock to Reverse Split on Thursday, March 23rd (NASDAQ:RDHL)
March 22, 2023 | Weiss Ratings (Ad)
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
March 19, 2023 | americanbankingnews.com
RedHill Biopharma Stock Set to Reverse Split on Thursday, March 23rd (NASDAQ:RDHL)
March 16, 2023 | finance.yahoo.com
RedHill Biopharma Announces Plan to Implement ADS Ratio Change
March 8, 2023 | finance.yahoo.com
RedHill Biopharma Announces Definitive Agreement for Up To $6 Million Private Placement with a Single Investor
February 28, 2023 | finance.yahoo.com
RedHill's Opaganib Selected by the NIH Radiation and Nuclear Countermeasures Program
February 28, 2023 | finance.yahoo.com
RedHill Biopharma Ltd Announces RDHL Opaganib Selected by NIH RNCP For Development
March 22, 2023 | Weiss Ratings (Ad)
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
February 16, 2023 | baystreet.ca
RedHill Flat on Application for Oncology Drug
February 16, 2023 | finance.yahoo.com
RedHill Announces Positive MHRA Meeting and Planned UK Marketing Authorisation Application of RHB-102 (BEKINDA®) for Oncology Support
February 16, 2023 | finance.yahoo.com
RedHill Biopharma Ltd Announces RedHill's RHB-102 Positive MHRA Meeting & MAA Plan
February 15, 2023 | finance.yahoo.com
RedHill Biopharma Announces Positive FDA Meeting Regarding Opaganib for Acute Nuclear Radiation Syndrome
February 10, 2023 | finance.yahoo.com
Raleigh pharma sheds debt in exchange for top-selling drug. Now what?
February 6, 2023 | finance.yahoo.com
RedHill Biopharma and HealthCare Royalty Agree to Extinguish All RedHill's Debt Obligations in Exchange for Movantik®
January 26, 2023 | finance.yahoo.com
RedHill Receives USPTO Notice of Allowance for a Patent Covering Phase 3-stage RHB-204 for the Treatment of NTM Disease
January 3, 2023 | msn.com
RedHill Biopharma Shares Jump After Data Publication From COVID-19 Study
January 3, 2023 | markets.businessinsider.com
RedHill Biopharma Reports Positive Data From Phase 2 Study Of RHB-107 In Symptomatic COVID-19
January 3, 2023 | msn.com
Why RedHill Biopharma Shares Are Trading Higher
January 3, 2023 | finance.yahoo.com
RedHill Announces Publication of Positive Phase 2 Study Results with Once-Daily Oral RHB-107 in Non-Hospitalized COVID-19
December 27, 2022 | finance.yahoo.com
2022 Year in Review: Layoffs hit Triangle biotech, pharma companies
December 7, 2022 | finance.yahoo.com
Aegis Capital Corp. Acted as Sole Bookrunner on an $8 Million Underwritten Public Offering for RedHill Biopharma Ltd. (NASDAQ:RDHL)
December 2, 2022 | finance.yahoo.com
RedHill Biopharma Prices $8.0 Million Underwritten Public Offering
November 29, 2022 | finance.yahoo.com
RedHill Biopharma Announces Q3/22 Results and Operational Highlights
November 24, 2022 | finance.yahoo.com
RedHill Says Opaganib Has Potential As Nuclear Radiation Protection For Homeland Security Countermeasures
November 24, 2022 | finance.yahoo.com
The RedHill Biopharma Ltd. (NASDAQ:RDHL) Analyst Just Cut Their Revenue Forecast By 23%
November 17, 2022 | finance.yahoo.com
RedHill Biopharma Announces Positive New Data with Opaganib for Nuclear Radiation Injury
See More Headlines
Receive RDHL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RedHill Biopharma and its competitors with MarketBeat's FREE daily newsletter.

RDHL Company Calendar

Last Earnings
11/30/2021
Today
3/22/2023
Next Earnings (Estimated)
3/23/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RDHL
CUSIP
N/A
CIK
1553846
Web
www.redhillbio.com
Phone
972-3541-3131
Fax
972-3541-3144
Employees
201
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($1.56)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-97,740,000.00
Net Margins
-116.69%
Pretax Margin
-116.69%
Return on Equity
-9,208.02%
Return on Assets
-52.82%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.43
Quick Ratio
0.36

Sales & Book Value

Annual Sales
$85.76 million
Price / Sales
0.15
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.17 per share
Price / Book
0.78

Miscellaneous

Outstanding Shares
96,430,000
Free Float
89,862,000
Market Cap
$12.81 million
Optionable
Optionable
Beta
2.28

Key Executives

  • Mr. Dror Ben-Asher (Age 56)
    Co-Founder, Chairman & CEO
    Comp: $884.67k
  • Mr. Micha Ben-Chorin (Age 53)
    Chief Financial Officer
    Comp: $548.14k
  • Mr. Gilead Raday MPhil (Age 47)
    MSc, Chief Operating Officer
    Comp: $539.74k
  • Mr. Adi Frish (Age 52)
    Chief Corp. & Bus. Devel. Officer
    Comp: $519.65k
  • Mr. Rick D. Scruggs (Age 62)
    Chief Commercial Officer, Pres of RedHill Biopharma Inc. & Director
    Comp: $736.35k
  • Dr. Mark L. Levitt M.D.
    Ph.D., Chief Scientific Officer
  • Ms. Alexandra Okmian
    Sr. Bus. Devel. & Investor Relations Mang.
  • Kristin Comer
    VP, Gen. Counsel & Chief Compliance Officer
  • Ms. Valerie Graceffa
    VP of Sales
  • Mr. Rob Jackson
    Sr. VP of Sales & Marketing

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













RDHL Stock - Frequently Asked Questions

How have RDHL shares performed in 2023?

RedHill Biopharma's stock was trading at $0.1403 on January 1st, 2023. Since then, RDHL stock has decreased by 5.3% and is now trading at $0.1328.
View the best growth stocks for 2023 here.

When is RedHill Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023.
View our RDHL earnings forecast.

How were RedHill Biopharma's earnings last quarter?

RedHill Biopharma Ltd. (NASDAQ:RDHL) posted its earnings results on Tuesday, November, 30th. The biotechnology company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by $0.02. The biotechnology company had revenue of $21.61 million for the quarter, compared to the consensus estimate of $23.41 million. RedHill Biopharma had a negative net margin of 116.69% and a negative trailing twelve-month return on equity of 9,208.02%. During the same quarter in the prior year, the business posted ($0.50) EPS.

When did RedHill Biopharma's stock split?

Shares of RedHill Biopharma reverse split on the morning of Thursday, March 23rd 2023. The 1-40 reverse split was announced on Thursday, March 23rd 2023. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, March 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What guidance has RedHill Biopharma issued on next quarter's earnings?

RedHill Biopharma updated its fourth quarter 2022 earnings guidance on Monday, March, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $13.50 million-$15.50 million, compared to the consensus revenue estimate of $18.10 million.

What other stocks do shareholders of RedHill Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RedHill Biopharma investors own include Agenus (AGEN), Sorrento Therapeutics (SRNE), Sangamo Therapeutics (SGMO), Verastem (VSTM), Amarin (AMRN), Aralez Pharmaceuticals (ARLZ), Inovio Pharmaceuticals (INO), Tesla (TSLA), Gilead Sciences (GILD) and NVIDIA (NVDA).

What is RedHill Biopharma's stock symbol?

RedHill Biopharma trades on the NASDAQ under the ticker symbol "RDHL."

Who are RedHill Biopharma's major shareholders?

RedHill Biopharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Millennium Management LLC (0.83%), Morgan Stanley (0.70%), Renaissance Technologies LLC (0.55%), Gagnon Securities LLC (0.52%), CLARET ASSET MANAGEMENT Corp (0.36%) and Belvedere Trading LLC (0.00%).

How do I buy shares of RedHill Biopharma?

Shares of RDHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is RedHill Biopharma's stock price today?

One share of RDHL stock can currently be purchased for approximately $0.13.

How much money does RedHill Biopharma make?

RedHill Biopharma (NASDAQ:RDHL) has a market capitalization of $12.81 million and generates $85.76 million in revenue each year. The biotechnology company earns $-97,740,000.00 in net income (profit) each year or ($1.56) on an earnings per share basis.

How many employees does RedHill Biopharma have?

The company employs 201 workers across the globe.

How can I contact RedHill Biopharma?

RedHill Biopharma's mailing address is 21 Ha'arba'a Street, Tel Aviv L3, 64739. The official website for the company is www.redhillbio.com. The biotechnology company can be reached via phone at 972-3541-3131, via email at investors@redhillbio.com, or via fax at 972-3541-3144.

This page (NASDAQ:RDHL) was last updated on 3/22/2023 by MarketBeat.com Staff